A Phase II Study of Epacadostat and Pembrolizumab in Patients with Imatinib-Refractory Advanced Gastrointestinal Stromal Tumors
Study of Epacadostat and Pembrolizumab in Patients Advanced Gastrointestinal Stromal Tumors (GIST)
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR1581
U.S. Govt. ID: NCT03291054
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to help patients diagnosed with advanced gastrointestinal stromal tumor (GIST), and treatment with imatinib has not controlled tumor growth. The purpose of this study is to see if epacadostat and pembrolizumab, will shrink cancer or stop cancer from growing.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with advanced gastrointestional stromal tumor (GIST)? Yes No
Is surgery an option for your GIST? Yes No
Have you had one, but fewer than four, previous therapies for metastatic disease? Yes No
Do you have a life expectancy of three months or more? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE